162 related articles for article (PubMed ID: 32656696)
1. Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.
Ghadir M; Khamseh ME; Panahi-Shamsabad M; Ghorbani M; Akbari H; Mehrjardi AZ; Honardoost M; Jafar-Mohammadi B
Endocrine; 2020 Sep; 69(3):596-603. PubMed ID: 32656696
[TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion.
Miao Y; Zong M; Jiang T; Yuan X; Guan S; Wang Y; Zhou D
Pituitary; 2016 Apr; 19(2):194-201. PubMed ID: 26809958
[TBL] [Abstract][Full Text] [Related]
3. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of Invasive Nonfunctional Pituitary Adenomas by Serum Extracellular Vesicles.
Wang H; Chen K; Yang Z; Li W; Wang C; Zhang G; Zhu L; Liu P; Yang Y
Anal Chem; 2019 Aug; 91(15):9580-9589. PubMed ID: 31264409
[TBL] [Abstract][Full Text] [Related]
5. circOMA1-Mediated miR-145-5p Suppresses Tumor Growth of Nonfunctioning Pituitary Adenomas by Targeting TPT1.
Du Q; Hu B; Feng Y; Wang Z; Wang X; Zhu D; Zhu Y; Jiang X; Wang H
J Clin Endocrinol Metab; 2019 Jun; 104(6):2419-2434. PubMed ID: 30721952
[TBL] [Abstract][Full Text] [Related]
6. Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas.
Yagnik G; Jahangiri A; Chen R; Wagner JR; Aghi MK
Mol Cell Endocrinol; 2017 May; 446():81-90. PubMed ID: 28214592
[TBL] [Abstract][Full Text] [Related]
7. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
Uraki S; Ariyasu H; Doi A; Takeshima K; Morita S; Inaba H; Furuta H; Fukuhara N; Inoshita N; Nishioka H; Nakao N; Yamada S; Akamizu T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325698
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.
Hosseinkhan N; Honardoost M; Emami Z; Cheraghi S; Hashemi-Madani N; Khamseh ME
Endocrine; 2022 Sep; 77(3):500-509. PubMed ID: 35711030
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas.
Yao X; Gao H; Li C; Wu L; Bai J; Wang J; Li Y; Zhang Y
J Neurooncol; 2017 Apr; 132(2):199-206. PubMed ID: 28255749
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of the sFRP and WIF1 genes in invasive non-functioning pituitary adenomas.
Song W; Qian L; Jing G; Jie F; Xiaosong S; Chunhui L; Yangfang L; Guilin L; Gao H; Yazhuo Z
Mol Cell Endocrinol; 2018 Oct; 474():168-175. PubMed ID: 29555596
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Radiographic Characteristics Related to Hyperprolactinemia in Nonfunctioning Pituitary Adenomas.
Park SS; Kim JH; Kim YH; Lee JH; Dho YS; Shin CS
World Neurosurg; 2018 Nov; 119():e1035-e1040. PubMed ID: 30144593
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative, antiinvasive, and proapoptotic activity of folate receptor α-targeted liposomal doxorubicin in nonfunctional pituitary adenoma cells.
Liu X; Ma S; Dai C; Cai F; Yao Y; Yang Y; Feng M; Deng K; Li G; Ma W; Xin B; Lian W; Xiang G; Zhang B; Wang R
Endocrinology; 2013 Apr; 154(4):1414-23. PubMed ID: 23462961
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior.
Vicchio TM; Aliquò F; Ruggeri RM; Ragonese M; Giuffrida G; Cotta OR; Spagnolo F; Torre ML; Alibrandi A; Asmundo A; Angileri FF; Esposito F; Polito F; Oteri R; Aguennouz MH; Cannavò S; Ferraù F
J Endocrinol Invest; 2020 Jul; 43(7):947-958. PubMed ID: 31939196
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous preoperative pituitary adenoma resolution following apoplexy: a case presentation and literature review.
Eichberg DG; Di L; Shah AH; Kaye WA; Komotar RJ
Br J Neurosurg; 2020 Oct; 34(5):502-507. PubMed ID: 30450986
[No Abstract] [Full Text] [Related]
16. Correlations of vascular architecture and angiogenesis with pituitary adenoma histotype.
Takano S; Akutsu H; Hara T; Yamamoto T; Matsumura A
Int J Endocrinol; 2014; 2014():989574. PubMed ID: 25431591
[TBL] [Abstract][Full Text] [Related]
17. CXCL12-regulated miR-370-3p functions as a tumor suppressor gene by targeting HMGA2 in nonfunctional pituitary adenomas.
Cai F; Dai C; Chen S; Wu Q; Liu X; Hong Y; Wang Z; Li L; Yan W; Wang R; Zhang J
Mol Cell Endocrinol; 2019 May; 488():25-35. PubMed ID: 30853598
[TBL] [Abstract][Full Text] [Related]
18. A Novel Invasive-Related Biomarker in Three Subtypes of Nonfunctioning Pituitary Adenomas.
Chen Y; Chuan HL; Yu SY; Li CZ; Wu ZB; Li GL; Zhang YZ
World Neurosurg; 2017 Apr; 100():514-521. PubMed ID: 28093347
[TBL] [Abstract][Full Text] [Related]
19. Identification of Important Invasion-Related Genes in Non-functional Pituitary Adenomas.
Joshi H; Vastrad B; Vastrad C
J Mol Neurosci; 2019 Aug; 68(4):565-589. PubMed ID: 30982163
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of invasive non-functional pituitary adenomas using exosomal biomarkers.
Ren Y; Wang Y; Bao X; Feng M; Xing B; Lian W; Yao Y; Wang R
Clin Chim Acta; 2022 Apr; 529():25-33. PubMed ID: 35085587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
